The present invention relates to peptides presented on the cell surface of cells in the MHC class I (MHC I) context in which the invariant chain has been engineered to favor loading of specific antigens and generate CD8.sup.+ T-cell activation

This document provides methods and materials for treating cancer. For example, methods and materials for treating cancer using combinations of antigens are provided. For example, VSV vectors designed to express a GNAQ antigen, a TYRP1 antigen, and an N-RAS antigen can be used to reduce the number of cancer cells (e.g., uveal melanoma cells) within a mammal (e.g., a human). In some cases, VSV vectors designed to express a BRAF antigen, a TOPO-11a antigen, and a YB-I antigen can be used to reduce the number of cancer cells (e.g., skin melanoma cells) within a mammal (e.g., a human). The composition can comprise less than 50 separate nucleic acid molecules.

The field of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.

The present invention relates to a modified virus-like particle of RNA bacteriophage AP205 (AP205 VLP) comprising AP205 coat protein dimers to which antigenic polypeptides are fused at the N-terminus and/or at the C-terminus. The modified AP205 VLPs can be used as a platform, in particular for vaccine development, in generating immune responses against a variety of antigens.

Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-? superfamily of proteins.

Provided are compositions that include one or more peptides, wherein each peptide is at least 8 amino acids long and has an amino acid sequence as set forth in any of SEQ ID NOs: 1-45. Also provided are in vitro populations of dendritic cells that include the disclosed compositions, in vitro populations of CD8.sup.+ T cells capable of being activated upon being brought into contact with the disclosed populations of dendritic cells, antibodies or antibody-like molecules that specifically bind to complexes of MHC class I molecules and the disclosed peptides, methods for treating and/or preventing cancer such as leukemia using the disclosed compositions and/or populations, methods for making cancer vaccines using the disclosed compositions, methods for screening target peptides for inclusion in an immunotherapy composition, methods for determining a prognosis of a leukemia patient, and kits that include at least one of the disclosed peptides.

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of cancer or tumour diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.

In some aspects, the invention relates to compositions and methods of generating antigens, wherein the antigen is a biomolecule that is modified by a reactive oxygen species or a reactive nitrogen species. In some aspects, the invention relates to compositions and methods of generating antibodies that bind to biomolecules that have been modified by a reactive oxygen species or a reactive nitrogen species. In some aspects, the invention relates to compositions and methods of generating antibodies that bind to novel epitopes on unmodified biomolecules. In some aspects, the invention relates to the induction of active immunotherapeutic processes (e.g., using preventive or therapeutic vaccines), which may comprise administering neo-antigens generated through methods and compositions described herein.

Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-? superfamily of proteins.

The present disclosure relates to compositions and methods for treating disease. More particularly, the disclosure relates to synthetic proteins and their use for treating cancer.